Literature DB >> 12143944

Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients.

Ken Kanamasa1, Takahiro Hayashi, Akio Kimura, Akiko Ikeda, Kinji Ishikawa.   

Abstract

This study was performed to investigate the effects of continuous dosing of oral, transdermal (patch), and a combination of the two with nitrate treatments on cardiac events in patients with healed myocardial infarction. In total, 1,291 patients with healed myocardial infarction were assigned 2 groups: treatment with nitrates (n=713) or nontreatment (n=578). Nitrate treatment was subdivided into 3 groups: patch group (n=149), oral group (n=504), and combination group (n=60). The mean observation period was 17.4 +/- 21.1 months. Primary end points were nonfatal and fatal recurrent myocardial infarction, death from congestive heart failure, and sudden death. Baseline characteristics were also compared among the 4 groups to determine any effects on outcome. Among the patients with patch, oral, and combination groups, cardiac events occurred 3.4%, 6.7%, 10.0%, respectively, whereas only 2.9% of the patients treated without nitrates had cardiac events. The incidence of cardiac events was significantly greater in patients with oral nitrates and combination groups compared to patients without nitrates (p<0.01, respectively). Continuous dosing of long-term treatment with both oral and transdermal nitrates increased cardiac events in healed myocardial infarction patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12143944     DOI: 10.1177/000331970205300405

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

1.  Diabetes and chronic nitrate therapy as co-determinants of somatic DNA damage in patients with coronary artery disease.

Authors:  Maria Grazia Andreassi; Nicoletta Botto; Silvana Simi; Marta Casella; Samantha Manfredi; Marilena Lucarelli; Lucia Venneri; Andrea Biagini; Eugenio Picano
Journal:  J Mol Med (Berl)       Date:  2005-03-16       Impact factor: 4.599

2.  Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats.

Authors:  Anu Shilpa Krishnatry; Sun Mi Fung; Daniel A Brazeau; David Soda; Ho-Leung Fung
Journal:  Nitric Oxide       Date:  2010-12-13       Impact factor: 4.427

3.  Nitrates as a Marker of Multiple Co-morbidities and Increased Mortality in Patients Undergoing Percutaneous Coronary Intervention (PCI).

Authors:  Neil Yager; Sunjeev Konduru; Mikhail Torosoff
Journal:  Cureus       Date:  2022-03-26

4.  Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin.

Authors:  Anu Shilpa Krishnatry; Daniel A Brazeau; Ho-Leung Fung
Journal:  Nitric Oxide       Date:  2009-10-15       Impact factor: 4.427

Review 5.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

6.  Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.

Authors:  S William Tam; Michael L Sabolinski; Manuel Worcel; Milton Packer; Jay N Cohn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Authors:  Andreas Daiber; Thomas Münzel
Journal:  Antioxid Redox Signal       Date:  2015-09-24       Impact factor: 8.401

8.  Long-term oral nitrate therapy is associated with adverse outcome in diabetic patients following elective percutaneous coronary intervention.

Authors:  Kai Hang Yiu; Vincent Pong; Chung Wah Siu; Chu Pak Lau; Hung Fat Tse
Journal:  Cardiovasc Diabetol       Date:  2011-06-13       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.